Evidence map›Paper›PMID 33235448›Full record

ArticleInternational journal of nanomedicine2020

Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.

Haroon Rahim, Abdul Sadiq, Riaz Ullah, Ahmed Bari, Fazli Amin, Umar Farooq, Naeem Ullah Jan, Hafiz Majid Mahmood

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Haroon RahimDepartment of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.ORCID 0000-0002-4978-4331
Abdul SadiqDepartment of Pharmacy, University of Malakand, Chakdara, Khyber Pakhtunkhwa, Pakistan.
Riaz UllahDepartment of Pharmacognosy (MAPPRC), College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.
Ahmed BariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.ORCID 0000-0002-9447-2361
Fazli AminDepartment of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Umar FarooqLegacy Pharmaceutical (Pvt.) Ltd., Peshawar, Khyber Pakhtunkhwa, Pakistan.
Naeem Ullah JanDepartment of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Hafiz Majid MahmoodDepartment of Pharmacology, College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.ORCID 0000-0001-9215-0505
King Saud University · SASarhad University of Science and Information Technology · PKUniversity of Malakand · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the studies was to fabricate aceclofenac (AC) tablets using nanosuspension as granulating fluid to boost its rate of in vitro dissolution and eventually its oral bioavailability.

methodsThe optimized nanosuspension with particle size of 112±2.01 nm was fabricated using HPMC 1% (w/v), PVP-K30 1% (w/v) and SLS 0.12% (w/v) at 400 watts of ultrasonication energy for 15 min duration and 3 sec pause. Then, the optimized aceclofenac nanosuspension was used as granulating fluid for aceclofenac tablets formulation. The characterization was performed using Malvern zetasizer, SEM, TEM, DSC and P-XRD. The granules were evaluated for the bulk and tapped densities, Hausner's ratio, angle of repose and their resulted values were found within limit. The prepared tablets were tested for average weight, hardness, friability, disintegration, dissolution and in vivo bioavailability in rabbits.

resultsThe in vitro dissolution data showed the boosted rate of nanosuspension-based tablets compared to the microsuspension-based tablets. The in vivo bioavailability (in rabbits model) of aceclofenac nanosuspension-based tablets (ACN-1, ACN-2) proved an improved absorption as in comparison to the marketed formulation. The C

conclusionThis boosted in vitro and in vivo bioavailability may be attributed to reduced particle size of aceclofenac nanoformulations used in tablets. Finally, this will result in faster absorption of these fabricated tablets.

Indexed as

Administration, OralAnimalsBiological AvailabilityCalorimetry, Differential ScanningDiclofenacDrug LiberationKineticsNanoparticlesParticle SizeRabbitsSpectroscopy, Fourier Transform InfraredSuspensionsTabletsTime FactorsX-Ray DiffractionaceclofenacDiclofenacSuspensionsTabletsenhanced oral bioavailabilitynanosuspension-based tabletsrelease kinetics

Identifiers

PMID33235448
PMCPMC7680606
OpenAlexW3099386776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.